ZOMIG 2.5MG (ZOLMITRIPTAN) TABLETS 6`S

Migraine

Indicated for acute treatment of migraine with or without aura

2.5 mg PO/intranasally, initially, at onset of migraine

Dosing considerations

• May increase dose to 5 mg; not to exceed 5 mg per single dose; individual response varies
• May repeat dose if migraine has not resolved after 2 hr; not to exceed 10 mg/24 hr
• Safety not established for tablets in the treatment of >3 migraines/30 days or >4 migraines/30 days for the intranasal formulation

• Adverse Effects

  1-10%

  Dizziness (6-10%)

  Neck/throat/jaw pain (4-10%)

  Parasthesia (5-9%)

  Nausea (4-9%)

  Weakness (3-9%)

  Somnolence (5-8%)

  Warm/cold sensation (5-7%)

  Xerostomia (3-5%)

  Chest pain (2-4%)

  Diaphoresis (3%)

  Pain (2-3%)

  Dyspepsia (1-3%)

  Dysphagia (2%)

  Myasthenia (2%)

  Palpation (2%)

  Vertigo (2%)

  Hypoesthesia (1-2%)

  Myalgia (1-2%)

  <1%

  QT prolongation

  Bradycardia

  Tachycardia

  Thrombophlebitis

  Postural hypotension

  Hyperglycemia

  Alk phos increased

  Arthritis

  Twitching

  Myocardial infarction and artery vasospasm in patients with CAD risk factors